Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 11/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.35 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140459 | 0.93 | MAPT (0.43) | L3MBTL1PDE5ACCNE2CCNE1CDK2 | |
| SCHEMBL20140339 | 0.92 | L3MBTL1 (0.40) | L3MBTL1PDE5AMAPTCYP1A2CYP2C19 | |
| SCHEMBL20161316 | 0.91 | GRIN2B (0.36) | L3MBTL1PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL20161154 | 0.89 | L3MBTL1 (0.50) | L3MBTL1PDE5AKDM4ECYP1A2CYP3A4 | |
| SCHEMBL20139619 | 0.87 | L3MBTL1 (0.45) | L3MBTL1PDE5AMAPTCYP1A2CYP3A4 | |
| SCHEMBL20161279 | 0.87 | L3MBTL1 (0.37) | L3MBTL1PDE5A | |
| SCHEMBL20139682 | 0.86 | PDE5A (0.42) | PDE5AAURKA | |
| SCHEMBL20148909 | 0.86 | L3MBTL1 (0.41) | L3MBTL1PDE5A | |
| SCHEMBL20161254 | 0.85 | PDE5A (0.40) | PDE5A | |
| SCHEMBL20140449 | 0.85 | PDE5A (0.40) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| EP-3538520-A2 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018111795-A2 | USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | L3MBTL1 4698/4885PDE5A 12/4885CCNE2 4036/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | L3MBTL1 4695/4885PDE5A 12/4885CCNE2 4060/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | L3MBTL1 4695/4885PDE5A 12/4885CCNE2 4060/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | L3MBTL1 4698/4885PDE5A 12/4885CCNE2 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.